QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
NASDAQ:SRDX

Surmodics - SRDX Stock Forecast, Price & News

$30.27
-0.13 (-0.43%)
(As of 10/3/2022 12:00 AM ET)
Add
Compare
Today's Range
$30.07
$31.66
50-Day Range
$28.84
$38.92
52-Week Range
$28.27
$58.95
Volume
34,364 shs
Average Volume
42,260 shs
Market Capitalization
$423.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.00

Surmodics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
91.6% Upside
$58.00 Price Target
Short Interest
Bearish
2.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.52
Upright™ Environmental Score
News Sentiment
1.16mentions of Surmodics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.08) to $0.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

665th out of 1,093 stocks

Surgical & Medical Instruments Industry

70th out of 105 stocks

SRDX stock logo

About Surmodics (NASDAQ:SRDX) Stock

Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

SRDX Stock News Headlines

Surmodics, Inc.
Surmodics Reports Third Quarter Fiscal 2022 Results
Surmodics SRDX Trading Report
See More Headlines
Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

SRDX Company Calendar

Last Earnings
7/27/2022
Today
10/03/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:SRDX
CUSIP
86887310
Employees
389
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$58.00
High Stock Price Forecast
$58.00
Low Stock Price Forecast
$58.00
Forecasted Upside/Downside
+91.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$4.24 million
Pretax Margin
-16.61%

Debt

Sales & Book Value

Annual Sales
$105.14 million
Cash Flow
$0.95 per share
Book Value
$10.10 per share

Miscellaneous

Free Float
13,053,000
Market Cap
$423.48 million
Optionable
Optionable
Beta
0.96

Social Links


Key Executives

  • Mr. Gary R. MaharajMr. Gary R. Maharaj (Age 59)
    CEO, Pres & Director
    Comp: $1.29M
  • Mr. Timothy J. Arens (Age 55)
    Sr. VP of Fin. & Information Technology and CFO
    Comp: $572k
  • Mr. Gordon S. Weber (Age 59)
    Sr. VP of Legal, Gen. Counsel & Sec.
    Comp: $573.67k
  • Mr. Joseph J. StichMr. Joseph J. Stich (Age 57)
    Sr. VP of HR & Pres of In Vitro Diagnostics
    Comp: $570.92k
  • Ms. Teryl L. W. Sides (Age 52)
    Sr. VP & Pres of Vascular Interventions
    Comp: $638.67k
  • Mr. John D. Manders (Age 41)
    Corp. Controller & Principal Accounting Officer
  • Mr. Charles W. OlsonMr. Charles W. Olson (Age 58)
    Sr. VP & Pres of Medical Device Coatings
  • Mr. Gregg S. Sutton (Age 62)
    VP of R&D - Medical Devices













SRDX Stock - Frequently Asked Questions

Should I buy or sell Surmodics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares.
View SRDX analyst ratings
or view top-rated stocks.

What is Surmodics' stock price forecast for 2022?

1 equities research analysts have issued 12-month price objectives for Surmodics' shares. Their SRDX share price forecasts range from $58.00 to $58.00. On average, they anticipate the company's share price to reach $58.00 in the next twelve months. This suggests a possible upside of 87.9% from the stock's current price.
View analysts price targets for SRDX
or view top-rated stocks among Wall Street analysts.

How have SRDX shares performed in 2022?

Surmodics' stock was trading at $48.15 at the beginning of the year. Since then, SRDX shares have decreased by 35.9% and is now trading at $30.87.
View the best growth stocks for 2022 here
.

When is Surmodics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our SRDX earnings forecast
.

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) announced its quarterly earnings results on Wednesday, July, 27th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.05. The firm earned $24.85 million during the quarter, compared to analysts' expectations of $25.48 million. Surmodics had a negative trailing twelve-month return on equity of 8.22% and a negative net margin of 13.11%.

What guidance has Surmodics issued on next quarter's earnings?

Surmodics issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of -$1.23--$1.08 for the period, compared to the consensus estimate of -$1.23. The company issued revenue guidance of $97.00 million-$99.00 million, compared to the consensus revenue estimate of $99.76 million.

What is Gary Maharaj's approval rating as Surmodics' CEO?

8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

What is Surmodics' stock symbol?

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

How do I buy shares of Surmodics?

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surmodics' stock price today?

One share of SRDX stock can currently be purchased for approximately $30.87.

How much money does Surmodics make?

Surmodics (NASDAQ:SRDX) has a market capitalization of $431.87 million and generates $105.14 million in revenue each year. The company earns $4.24 million in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does Surmodics have?

The company employs 389 workers across the globe.

How can I contact Surmodics?

Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The official website for the company is www.surmodics.com. The company can be reached via phone at (952) 500-7000, via email at ir@surmodics.com, or via fax at 952-500-7001.

This page (NASDAQ:SRDX) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.